Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

IntroductionPatients with cancer are at increased risk of morbidity and mortality from COVID-19 but were underrepresented in pivotal vaccine trials. Data on the magnitude and determinants of immune responses to mRNA SARS-CoV-2 vaccination in this population remain limited.MethodsI-SPARC is a prospec...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Soraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, Hafid Dahma, Sigi van den Wijngaert, Mounia Jaouart, Chiara Dauccia, Chiara Molinelli, Elisa Agostinetto, Angela Loizidou, Donatienne Taylor, Anais Boisson, Soizic Garaud, Chloé Spilleboudt, Jose Vicente Cardona, Peter Ramge, Bogdana Ioana Balas, Mohammed Bajji, Fanny George, Tabatha Delsaute, Marianne Paesmans, Lieveke Ameye, Martine Piccart, Evandro de Azambuja, Karen Willard-Gallo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-05-01
coleção:	Frontiers in Immunology
Assuntos:	adaptive immunity cancer immunology humoral immune response immune response determinants mRNA vaccine immunogenicity SARS-CoV-2 vaccination
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1815933/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!